Clinical Trial

A Clinical Study of MK-8527 in Participants With Mild and Moderate Hepatic Impairment (MK-8527-015)

Completed Phase 1
View on ClinicalTrials.gov →
Summary
The purpose of this study is to learn what happens to MK-8527 in a person's body over time (a pharmacokinetic \[PK\] study). Researchers will compare what happens to MK-8527 in the body when it is given to healthy participants and participants with mild and moderate hepatic (liver) impairment.
Protocol Amendment History 5 amendments
This ClinicalTrials.gov record has been amended 5 times since 2025-06-09; most recent amendment 2026-02-25.
Status change: Active, Not Recruiting → Completed 2026-02-25
Status change: Recruiting → Active, Not Recruiting 2026-01-12
Status change: Not Yet Recruiting → Recruiting 2025-08-27
Trial Details
NCT Number NCT07025551
Lead Sponsor Merck Sharp & Dohme LLC
Conditions Hepatic Impairment, Healthy Participants
Enrollment 18 participants
Start Date 2025-09-19
Primary Completion 2026-02-13 (estimated)
Study Completion 2026-02-13 (estimated)
Updated on ClinicalTrials.gov 2026-02-27